Publications by authors named "Sara Redondo"

Claim this Profile
S
Standard Versus Reduced-Doses of Post-Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation.
Sara Redondo, Irene García-Cadenas, Albert Esquirol, Eva Iranzo, Miguel Arguello-Tomas

Eur J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to: "Comparison of three strategies of GvHD prophylaxis after T-cell replete haploidentical hematopoietic transplantation: Tacrolimus vs calcineurin inhibitors-MMF vs sirolimus-MMF" Journal: Transplant Cell Ther. 2024 Oct;30(10):1025.e1-1025.e14. doi: 10.1016/j.jtct.2024.07.027.
Albert Esquirol, Maria Jesus Pascual, Juan Montoro, José Luis Piñana, Christelle Ferrà, Sara Redondo

Transplant Cell Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Clinical Validation of Liquid Chromatography-Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A First Step Towards Optimized Treatment.
Sara Redondo, María Costa, Maria-Estela Moreno-Martinez, Miguel Arguello-Tomas, Mireia Riba

Eur J Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
Virginia Escamilla-Gómez, Valentín García Gutiérrez, Patricia Alcalde-Mellado, Beatriz Astibia-Mahillo, Anabelle Chinea-Rodriguez, Sara Redondo

Bone Marrow Transplant· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.
Sara Redondo, Irene García-Cadenas, Albert Esquirol, J M Portos, Eva Iranzo

Eur J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil.
Albert Esquirol, Maria Jesus Pascual, Juan Montoro, José Luis Piñana, Christelle Ferrà, Sara Redondo

Transplant Cell Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement.
Maria-Estela Moreno-Martinez, Mireia Riba, Irene García-Cadenas, Albert Esquirol, Marta Yusta, Sara Redondo

Front Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.
Albert Esquirol, Irene Garcia Cadenas, Silvana Novelli, Ana Garrido, Ana Carolina Caballero, Sara Redondo

Ann Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center.
Miguel Arguello-Tomas, Nil Albiol, Paola Jara, Irene Garcia-Cadenas, Sara Redondo

Leuk Lymphoma· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI.
Sara Redondo, Irene García-Cadenas, Antonio Vila, Albert Esquirol, J M Portos

Eur J Haematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
Irene García-Cadenas, Sara Redondo, Albert Esquirol, J M Portos, Silvana Novelli

Transplant Cell Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of a New Model of Care for Allogeneic Stem Cell Transplantation Recipients Facilitated by eHealth: The MY-Medula Pilot Study.
Sara Redondo, Anna De Dios, Mar Gomis-Pastor, Albert Esquirol, Olga Aso

Transplant Cell Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
Sara Redondo, Albert Esquirol, Silvana Novelli, Ana Carolina Caballero, Ana Garrido

Transplant Cell Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia.
María Poza, Rodrigo Íñiguez, Irene Zamanillo, Sara Redondo, Rafael Alonso

Ther Adv Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
Valentín García-Gutiérrez, María T Gómez-Casares, José M Puerta, Juan M Alonso-Domínguez, Santiago Osorio, Sara Redondo

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.
Francisco Cervantes, Juan-Gonzalo Correa, Isabel Pérez, Valentín García-Gutiérrez, Sara Redondo

Ann Hematol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis